Cellenkos - Crunchbase Company Profile & Funding

Q: Where is Cellenkos's headquarters?

Cellenkos is located in Houston, Texas, United States.

Q: When was the last funding round for Cellenkos?

Cellenkos closed its last funding round on obfuscated from a Series A round.

Q: How much funding has Cellenkos raised to date?

Cellenkos has raised obfuscated.

Overview

Cellenkos

Total Funding

obfuscation

Growth Score

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

See more interactive data and historical milestones on desktop for the best experience

About Cellenkos

CB Rank

21334

Cellenkos is a clinical stage biotech company.

Acquired by

Global Cord Blood

Founded

obfuscation

Private

Series A

Houston, Texas, United States

11-50

www.cellenkosinc.com/

Biotechnology

Funding Rounds

Series A

OBF

obfuscation

Key People

Simrit Parmar: Founder
Kim Chuan Leong: Chairman and Chief Financial Officer

Details

Sub-Organization of

Global Cord Blood

Legal Name

Cellenkos® Inc.

Operating Status

Active

Company Type

For Profit

Founders

Simrit Parmar

About the Company

Cellenkos is a clinical-stage biotech company focused on the development and commercialization of transformative novel allogeneic Treg cell therapies to treat autoimmune and inflammatory disorders.

Phone Number

(800) 217-8247

Diversity Spotlight

Women Founded

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

CK0801

An allogeneic umbilical cord blood-derived regulatory T cell therapy for treating bone marrow failure syndromes.

CK0804

An allogeneic umbilical cord blood-derived regulatory T cell therapy used as add-on treatment for myelofibrosis patients with suboptimal response to ruxolitinib.

Research & Development

Cellenkos is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated

...

Unlock More with Crunchbase Pro

Full access to financial & funding data on unlimited profiles
Export up to 2k results/month for analysis
Track market signals on competitors, products, and R&D
Preview private company insights and predictions

Financials

Company Funding

Funding Rounds

Investors

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A

Funding Rounds

Total Funding Amount

obfuscation

Number of Funding Rounds

Unlock company funding data, including rounds, dates, amounts, and investors.

Announced Date	Transaction Name	Number of Investors	Money Raised	Lead Investors	Funding Type
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A
obfuscated obfuscation	Series A - Cellenkos	1	obfuscated obfuscation	BVCF	Series A

Investors

Unlock company funding data, including rounds, dates, amounts, and investors.

Investor Name	Lead Investor	Funding Round	Partners
BVCF	Yes	Series A - Cellenkos	Zhi Yang
BVCF	Yes	Series A - Cellenkos	Zhi Yang
BVCF	Yes	Series A - Cellenkos	Zhi Yang
BVCF	Yes	Series A - Cellenkos	Zhi Yang
BVCF	Yes	Series A - Cellenkos	Zhi Yang